AstraZeneca’s Covid vaccine is the third one to prove highly effective in late-stage trials. AstraZeneca Executive Vice President Ruud Dobber explains differentiators of his company’s vaccine, and why between his company, Pfizer, and Moderna, he has high hopes for an accessible vaccine. New York Times columnist Thomas Friedman discusses the next steps in the race for a vaccine and in the Presidential transition. Plus, political pollster and strategist Frank Luntz unpacks what’s at stake on the ballots in Georgia. 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.